A recent retrospective case-control study has revealed that while patients diagnosed with sudden sensorineural hearing loss (SSNHL) exhibit distinct systemic inflammatory and metabolic profiles compared to healthy controls, these routinely measured blood biomarkers do not independently determine the initial severity of hearing impairment once demographic and broader metabolic factors are taken into account. The study, which evaluated data from 613 adult inpatients with SSNHL and 850 healthy individuals, underscores the complexity of the systemic milieu associated with this acute auditory disorder. Researchers found that while markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and various lipid parameters significantly differentiate SSNHL patients from the general healthy population, these clinical variables largely lose their predictive power regarding the magnitude of initial pure-tone average (PTA)-based hearing loss after adjusting for essential covariates including age, sex, glucose levels, triglycerides, and high-density lipoprotein cholesterol.
Sudden sensorineural hearing loss is defined by the Chinese Guideline for Diagnosis and Treatment of Sudden Deafness (2015) as an unexplained sudden hearing loss occurring within 72 hours, characterized by a hearing decrease of 20 dB HL or greater across at least two adjacent frequencies. Because the inner ear is highly dependent on a continuous blood supply and possesses a limited collateral vascular network, it is particularly susceptible to systemic perturbations, including metabolic stress and inflammatory responses. Although clinicians have long utilized pure-tone audiometry as the gold standard for assessment, the biological mechanisms responsible for the variation in initial hearing thresholds remain poorly understood, leading many to investigate whether simple, readily available blood biomarkers might offer insight into the systemic background of severe clinical presentations.
The study, conducted at Nanjing Tongren Hospital between January 2020 and December 2024, sought to address whether systemic biomarkers could distinguish between various stages of initial hearing impairment, ranging from mild to profound. The investigators included adult inpatients who completed pure-tone audiometry and provided baseline laboratory results, while excluding individuals with pre-existing chronic ear diseases, autoimmune disorders, or other systemic conditions that might confound the analysis. Healthy controls were selected from individuals who underwent routine health examinations during the same period and lacked documented ear or systemic inflammatory conditions. The researchers classified hearing loss into mild (≤ 40 dB HL), moderate (41–60 dB HL), severe (61–80 dB HL), and profound (> 80 dB HL) categories, providing a granular look at how biomarker levels shifted across the clinical spectrum of the disease.
Initial case-control comparisons indicated that patients with SSNHL presented with a significantly different systemic profile than healthy controls. Specifically, the SSNHL cohort exhibited higher levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), glucose, neutrophil counts, platelet counts, mean platelet volume, and apolipoprotein A1, alongside elevated NLR and PLR indices. Conversely, these patients showed lower lymphocyte counts and triglyceride levels compared to the control group. These standardized mean differences provided clear evidence that systemic inflammatory and metabolic pathways are active during the acute phase of SSNHL. However, the study design explicitly separated the findings regarding disease occurrence—how SSNHL patients differ from healthy controls—from the findings regarding disease severity—how biomarkers differ among patients with varying degrees of hearing impairment.
When the researchers turned their attention to the within-group severity analysis, they discovered that most patients presented with mild or moderate hearing loss, with 320 patients (52.2%) in the mild category and 155 (25.3%) in the moderate category. The severe and profound groups comprised 88 (14.4%) and 50 (8.1%) of the patients, respectively. Statistical analysis showed that while age increased significantly with greater hearing-loss severity, the relationship between inflammatory markers like NLR and PLR and the clinical severity of hearing loss was inconsistent. These findings suggest that although systemic inflammation is likely a hallmark of the condition, these specific markers appear more relevant for identifying the presence of the disorder rather than predicting its initial severity.
A critical component of the investigation was the evaluation of albumin, which reflects a patient’s overall nutritional and inflammatory status. In the biomarker-only ordinal logistic regression model, lower serum albumin levels were significantly associated with greater hearing-loss severity, with an odds ratio of 0.928. However, this association was heavily attenuated in subsequent multivariable models. When the researchers adjusted for demographic factors like age and sex, and later for broader metabolic indicators such as glucose, triglycerides, and high-density lipoprotein cholesterol, the statistical significance of the association between albumin and hearing-loss severity disappeared. In the fully adjusted model, the odds ratio shifted to 0.970, suggesting that albumin levels do not independently explain the magnitude of cochlear injury in this clinical context.
The study also utilized ordinal logistic regression to determine which variables independently predicted the severity of initial presentation. While albumin and other inflammatory markers failed to demonstrate independence, glucose levels, age, and male sex remained significantly associated with greater severity even after full adjustment for all included covariates. These results imply that while metabolic dysregulation plays a role in the clinical severity of SSNHL, the specific contributions of inflammation as measured by blood routine markers are complex and likely intertwined with other physiological variables. The researchers emphasized that these findings do not establish causality, but rather highlight that glucose-related metabolic factors might contribute to the clinical burden observed at admission.
Regression diagnostics were employed to ensure the robustness of the findings, with variance inflation factor (VIF) values remaining below 1.5, confirming the absence of problematic multicollinearity across the models. The approximate parallel-lines test for the proportional odds assumption was not rejected, providing further confidence in the validity of the ordinal logistic regression approach. Sensitivity analyses, including winsorization and log-transformation of skewed variables like NLR and PLR, yielded results consistent with the primary findings, reinforcing the conclusion that these routine biomarkers, while diagnostic of the condition’s presence, are limited in their ability to act as independent predictors of severity.
The researchers noted several study limitations, including the retrospective, single-center design which may introduce potential selection bias. Furthermore, the absence of systematic pure-tone audiometry for the control group meant that subclinical hearing difficulties in that cohort could not be definitively ruled out. Other potential clinical confounders—such as the exact duration of symptoms before admission, timing of treatment, specific medication use, and the presence of comorbid conditions like hypertension or diabetes—were not uniformly available in the dataset and thus could not be fully adjusted for in the final analysis. These gaps in data highlight the need for future prospective studies that incorporate standardized audiometry, detailed longitudinal treatment outcomes, and a more comprehensive capture of patient history.
Ultimately, the study concludes that routine blood biomarkers should be viewed as complementary tools that provide context regarding the systemic inflammatory and metabolic state of SSNHL patients, rather than as a replacement for formal audiological assessment. Pure-tone audiometry remains the essential standard for defining hearing-loss severity and guiding treatment protocols. While albumin may serve as a useful candidate marker for systemic nutritional-inflammatory status, its clinical interpretation must be cautious, avoiding the leap to mechanistic claims about direct cochlear injury. The findings provide a clearer understanding of the systemic nature of SSNHL while delineating the boundaries of what routine laboratory testing can tell clinicians about the immediate severity of this debilitating condition.
To establish baseline hearing measurements, the investigators calculated each patient’s pure-tone average as the mean air-conduction threshold across 0.25, 0.5, 1, 2, 4, and 8 kilohertz. The hospital’s ethics committee approved the retrospective protocol under the Declaration of Helsinki, waiving individual informed consent because anonymized electronic records were evaluated. Consecutive eligible inpatient cases over the five-year window determined the cohort size without an a priori sample size calculation. Demographic comparisons demonstrated well-balanced baseline distributions between the study groups: the sudden hearing loss cohort had a median age of 45 years with an interquartile range of 34 to 58 years, comprising 278 men (45.4 percent), while the healthy control cohort similarly exhibited a median age of 45 years with an interquartile range of 39 to 51 years, including 390 men (45.9 percent).
Detailed laboratory examinations across the four audiometric severity groups revealed distinct biochemical trajectories despite the absence of independent multivariable associations. Median serum albumin concentrations declined progressively from 43.70 grams per liter in mild cases to 43.60 grams per liter in moderate, 43.10 grams per liter in severe, and 42.50 grams per liter in profound cases, demonstrating a statistically significant downward trend. Coagulation and lipid parameters also displayed divergent patterns: high-density lipoprotein cholesterol levels tended to decrease as hearing impairment worsened, whereas circulating fibrinogen, D-dimer, glucose, and triglycerides exhibited upward trends. To enhance clinical interpretability during regression modeling, the researchers scaled age per decade and the platelet-to-lymphocyte ratio per ten units, confirming model improvements using log-likelihood, Akaike information criterion, and McFadden pseudo-R-squared statistics.
The investigators also highlighted specific data structure considerations that framed their statistical findings. Blood samples were captured at admission prior to major systemic interventions, but serum albumin measurements were not systematically collected among routine health-examination controls, restricting direct case-control comparisons for that biomarker. Furthermore, intermediate audiometric frequencies of 3 and 6 kilohertz were not consistently recorded across the retrospective electronic charts and were consequently excluded from core threshold calculations.
Subject of Research: Clinical relationship between systemic biomarkers and sudden sensorineural hearing loss severity
Article Title: Systemic inflammatory and metabolic biomarkers in relation to initial hearing loss severity in sudden sensorineural hearing loss
Article References: Han, J., Ji, W., Zhang, X., & Tong, H. (2026). Systemic inflammatory and metabolic biomarkers in relation to initial hearing loss severity in sudden sensorineural hearing loss. Head & Face Medicine, 22(1), Article 83. https://doi.org/10.1186/s13005-026-00647-5
Image Credits: AI Generated
DOI: 10.1186/s13005-026-00647-5
Keywords: Sudden Sensorineural Hearing Loss, SSNHL, Systemic Inflammation, Metabolic Biomarkers, Pure-tone Audiometry, NLR, PLR, Clinical Biochemistry, Retrospective Study, Hearing Impairment Severity, Albumin, LDL-C, Glucose, Health Examination, Auditory Disorders, Inflammatory Indices, Lipid Metabolism, Clinical Prognostics
News Source: Ophelia Keating. (November 18, 2026). Systemic Biomarkers Do Not Independently Predict Initial Sudden Sensorineural Hearing Loss Severity. Scienmag.



